Smoking Cessation > Effectiveness/Harms of Behavior Change on Clinical Outcomes Author: Kumanan Wilson, MD
Editorial changes - 2009-11-18
Author information and module status
Key Points
Population at Risk
Effectiveness/Harms of Counseling or Intervention on Changing Behavior
Effectiveness/Harms of Behavior Change on Clinical Outcomes
Direct Effectiveness of Intervention/Counseling on Clinical Outcomes
Timeline
Cost-Effectiveness
Patient Education
Referral/Consultation
Guidelines

Tables
References
What's New
Patient Information
Additional Resources
Tools

Quality Measures Quality Measures
Recommendation
Recognize that smoking cessation may lead to weight gain or produce depressive symptoms.B
  • Weight gain:
    • Smoking cessation is associated with a mean increase in weight of 5 kg
  • Depression:
    • Smoking cessation may produce depressive symptoms that are severe enough to warrant treatment, particularly in persons with a history of major depression

Evidence:

  • Weight gain:
    • In a study of 5247 patients age 35 and older, it was found that persons who had quit smoking were significantly heavier than patients who smoked. Men who were former smokers were on average 4.4 kg heavier than men who continued smoking. Women who were former smokers were on average 5.0 kg heavier than women who continued smoking (70).
  • Depression:
    • A study enrolled 100 smokers with a history of major depression not currently requiring treatment in a 2-month smoking cessation program. The OR for an episode of major depression in patients who successfully quit compared to patients who did not was 7.17 (CI, 1.5 to 34.5) (71).

Comments:

  • Neither weight gain nor the risk of depression should discourage the initiation of smoking cessation interventions, although physicians should monitor for both.

FAQs
Edward Ellerbeck, MD, MPH, editorial consultant, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Kumanan Wilson, MD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Steven E. Weinberger, MD, FACP, Acting Editor, PIER, has stock holdings in Glaxosmithkline and Abbott.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2009 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.